Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Stephan L M Peters"'
Autor:
Kathinka W E M van Hooren, Léon J A Spijkers, Dorothee van Breevoort, Mar Fernandez-Borja, Ruben Bierings, Jaap D van Buul, Astrid E Alewijnse, Stephan L M Peters, Jan Voorberg
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91346 (2014)
Sphingosine-1-phosphate (S1P) is an agonist for five distinct G-protein coupled receptors, that is released by platelets, mast cells, erythrocytes and endothelial cells. S1P promotes endothelial cell barrier function and induces release of endothelia
Externí odkaz:
https://doaj.org/article/ecb94040bd484e56aacf2e23ee062e9c
Autor:
Léon J A Spijkers, Rob F P van den Akker, Ben J A Janssen, Jacques J Debets, Jo G R De Mey, Erik S G Stroes, Bert-Jan H van den Born, Dayanjan S Wijesinghe, Charles E Chalfant, Luke MacAleese, Gert B Eijkel, Ron M A Heeren, Astrid E Alewijnse, Stephan L M Peters
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21817 (2011)
Hypertension is, amongst others, characterized by endothelial dysfunction and vascular remodeling. As sphingolipids have been implicated in both the regulation of vascular contractility and growth, we investigated whether sphingolipid biology is alte
Externí odkaz:
https://doaj.org/article/7ea95473f792457ab3148a3baa0d7cd5
Autor:
Léon J A Spijkers, Ben J A Janssen, Jelly Nelissen, Merlijn J P M T Meens, Dayanjan Wijesinghe, Charles E Chalfant, Jo G R De Mey, Astrid E Alewijnse, Stephan L M Peters
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e29222 (2011)
We have previously shown that essential hypertension in humans and spontaneously hypertensive rats (SHR), is associated with increased levels of ceramide and marked alterations in sphingolipid biology. Pharmacological elevation of ceramide in isolate
Externí odkaz:
https://doaj.org/article/46004c2b269246d28a6a3d335037f686
Autor:
Petra Keul, Marcel M. G. J. van Borren, Alexander Ghanem, Frank Ulrich Müller, Antonius Baartscheer, Arie O. Verkerk, Frank Stümpel, Jan Sebastian Schulte, Nazha Hamdani, Wolfgang A. Linke, Pieter van Loenen, Marek Matus, Wilhelm Schmitz, Jörg Stypmann, Klaus Tiemann, Jan‐Hindrik Ravesloot, Astrid E. Alewijnse, Sven Hermann, Léon J. A. Spijkers, Karl‐Heinz Hiller, Deron Herr, Gerd Heusch, Michael Schäfers, Stephan L. M. Peters, Jerold Chun, Bodo Levkau
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 5 (2016)
BackgroundSphingosine‐1‐phosphate plays vital roles in cardiomyocyte physiology, myocardial ischemia–reperfusion injury, and ischemic preconditioning. The function of the cardiomyocyte sphingosine‐1‐phosphate receptor 1 (S1P1) in vivo is un
Externí odkaz:
https://doaj.org/article/fbf5ff26565e41e1860b0d2d29621773
Autor:
Liffert Vogt, Carrie Ris-Stalpers, G. J. M. Veenboer, Stephan L. M. Peters, Fouad Amraoui, Gijs B. Afink, B.J.H. van den Born, H. Hassani Lahsinoui, N. van Vlies, Léon J. A. Spijkers
Publikováno v:
Scientific reports, 11(1):4387. Nature Publishing Group
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Preeclampsia, an important cause of maternal and fetal morbidity and mortality, is associated with increased sFLT1 levels and with structural and functional damage to the glycocalyx contributing to endothelial dysfunction. We investigated glycocalyx
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dee20188384cd8588c720b47334fcd2
https://pure.amc.nl/en/publications/soluble-syndecan1-and-glycosaminoglycans-in-preeclamptic-and-normotensive-pregnancies(d0591adb-ef6f-4a97-9d6e-35b9bdd94078).html
https://pure.amc.nl/en/publications/soluble-syndecan1-and-glycosaminoglycans-in-preeclamptic-and-normotensive-pregnancies(d0591adb-ef6f-4a97-9d6e-35b9bdd94078).html
Autor:
Paul M. H. Schiffers, Stephan L. M. Peters, Ben J. A. Janssen, Jo G. R. De Mey, Jelly Nelissen, Léon J. A. Spijkers, Pieter Lemkens, Merlijn J. Meens
Publikováno v:
Hypertension research, 40(8), 738-745. Nature Publishing Group
Hypertension Research, 40(8), 738-745. Nature Publishing Group
Hypertension Research, Vol. 40, No 8 (2017) pp. 738-745
Lemkens, P, Spijkers, L J, Meens, M J, Nelissen, J, Janssen, B, Peters, S L, Schiffers, P M & De Mey, J G 2017, ' Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR ', Hypertension Research, vol. 40, pp. 738-745 . https://doi.org/10.1038/hr.2017.38
Hypertension Research, 40(8), 738-745. Nature Publishing Group
Hypertension Research, Vol. 40, No 8 (2017) pp. 738-745
Lemkens, P, Spijkers, L J, Meens, M J, Nelissen, J, Janssen, B, Peters, S L, Schiffers, P M & De Mey, J G 2017, ' Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR ', Hypertension Research, vol. 40, pp. 738-745 . https://doi.org/10.1038/hr.2017.38
Endothelin 1 (ET-1), a potent vasoconstrictor, pro-mitogenic and pro-inflammatory peptide, may promote development of endothelial dysfunction and arterial remodeling. ET-1 can be formed through cleavage of big-ET-1 by endothelin-converting enzyme (EC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05127f324824704213ac38e10e6b9fac
https://doi.org/10.1038/hr.2017.38
https://doi.org/10.1038/hr.2017.38
Autor:
Léon J. A. Spijkers, Liffert Vogt, Hajar Hassani Lahsinoui, Stephan L. M. Peters, Bert-Jan H. van den Born, Gijs B. Afink, Carrie Ris-Stalpers, Fouad Amraoui, Urszula Osinska Warncke, Charles E. Chalfant, Dayanjan S. Wijesinghe
Publikováno v:
Pregnancy hypertension, 19, 100-105. Elsevier BV
Objectives: Ceramide is a sphingolipid with anti-angiogenic and pro-apoptotic properties that has shown to be increased in plasma of women with pre-eclampsia. We aimed to compare plasma and placental sphingolipid content among normotensive pregnant w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476197f6fd0363fa97fff2b5e334c0ce
https://pubmed.ncbi.nlm.nih.gov/31927322
https://pubmed.ncbi.nlm.nih.gov/31927322
Publikováno v:
British Journal of Pharmacology. 166:1411-1418
BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::368b9f7f1bc04e196fad29cab847c676
https://doi.org/10.1111/j.1476-5381.2012.01865.x
https://doi.org/10.1111/j.1476-5381.2012.01865.x
Autor:
Didier Rognan, Astrid E. Alewijnse, Dennis Verzijl, Stephan L. M. Peters, Rob Leurs, Pieter B. van Loenen, Chris de Graaf
Publikováno v:
European Journal of Pharmacology, 667(1-3), 105-12. Elsevier
van Loenen, P B, de Graaf, C, Verzijl, D, Leurs, R, Rognan, D, Peters, S L M & Alewijnse, A E 2011, ' Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor ', European Journal of Pharmacology, vol. 667, no. 1-3, pp. 105-12 . https://doi.org/10.1016/j.ejphar.2011.05.071
European journal of pharmacology, 667(1-3), 105-112. Elsevier
van Loenen, P B, de Graaf, C, Verzijl, D, Leurs, R, Rognan, D, Peters, S L M & Alewijnse, A E 2011, ' Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor ', European Journal of Pharmacology, vol. 667, no. 1-3, pp. 105-12 . https://doi.org/10.1016/j.ejphar.2011.05.071
European journal of pharmacology, 667(1-3), 105-112. Elsevier
The sphingosine-1-phosphate type 1 (S1P(1)) receptor is a new target in the treatment of auto-immune diseases as evidenced by the recent approval of FTY720 (Fingolimod). The ligand-binding pocket of the S1P(1) receptor has been generally characterise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39cab2df38b6b4ce31a7b178c8e8a7ac
https://doi.org/10.1016/j.ejphar.2011.05.071
https://doi.org/10.1016/j.ejphar.2011.05.071
Autor:
Stephan L. M. Peters, Elfaridah P. Frazier, Martin C. Michel, Pieter B. van Loenen, Tim Schneider, Carsten Sand, Martina B. Michel-Reher
Publikováno v:
European journal of pharmacology, 654(1), 86-91. Elsevier
Nebivolol is a selective β 1 -adrenoceptor antagonist which, in addition, displays endothelium-dependent vasodilating properties in humans and other species. β 3 -Adrenoceptors have been proposed to be a molecular target of nebivolol-induced vasodi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de57e2ed2fb441bc79beabdba29193fd
https://doi.org/10.1016/j.ejphar.2010.11.036
https://doi.org/10.1016/j.ejphar.2010.11.036